Here's a screenshot of what happened to drug industry stocks by the end of the day, courtesy our financial reporter Christopher Matthews. The plunge took place right after Trump's comments, and pharmaceutical stocks ended up down by more than 2 percent.
And: Nine of the 10 biggest losers in the S&P 500 Wednesday were either drug or biotech companies, including Bristol-Myers Squibb, down 5.3%, and Mylan, down 4.3%.
Diplomacy time: How does PhRMA, the main drug industry trade group, handle a situation like that? By not punching back at Trump. "We look forward to working with the new administration and Congress to advance proactive, practical solutions to improve the marketplace and make it more responsive to the needs of patients," PhRMA president and CEO Stephen Ubl said in a statement.
How not to become a target: AbbVie — the maker of the world's biggest selling drug, the rheumatoid arthritis treatment Humira — is now promising to keep its 2017 price increases below 10 percent, the third global drugmaker to make the promise, per Reuters.